Nectar Lifesciences P/E Ratio
Nectar Lifesciences (NECLIFE) P/E ratio is not applicable — EPS (TTM) ₹-13.40, 4 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has been reporting losses for 4 consecutive quarters. P/E ratio cannot be calculated for loss-making companies.
Consecutive Loss Quarters: 4
Current EPS: ₹-13.40
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -3.38 | -68 | Loss |
| Sept 2025 | -7.85 | -176 | Loss |
| Mar 2025 | -5.80 | -130 | Loss |
| Jun 2025 | -2.82 | -63 | Loss |
| Dec 2025 | 0.64 | 14 | Profit |
| Sept 2024 | 0.25 | 6 | Profit |
| Mar 2024 | 0.03 | 1 | Profit |
| Jun 2024 | 0.13 | 3 | Profit |
Healthcare Peers with Valid P/E Ratios — NECLIFE Comparison
Healthcare sector average P/E 54.83, median 30.68 — NECLIFE excluded (negative EPS).
Sector Average PE
54.83
Sector Median PE
30.68
Lowest PE
2.86
Profitable Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.5 | ₹30 | Low |
| Phaarmasia | PHRMASI | 4.06 | ₹68 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.97 | ₹7,724 | Low |
| Shelter Pharma | SHELTER | 5.34 | ₹49 | Low |
| Mono Pharmacare | MONOPHARMA | 6.25 | ₹20 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹77 | Low |
| Amwill Health Care | AMWILL | 7.81 | ₹89 | Low |
| Brooks Laboratories | BROOKS | 8.06 | ₹206 | Low |
| Royal Sense | ROYAL | 8.24 | ₹59 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see NECLIFE share price screener.
- Browse NECLIFE income statement for revenue, profit, balance sheet and cash flow data.
- Analyse NECLIFE shareholding pattern to track promoter, FII and institutional holdings.